Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 14/20 | 0.76 |
| ▸ | ESR2 | Q92731 | 14/20 | 0.76 |
| ▸ | XDH | P47989 | 1/20 | 0.42 |
| ▸ | ERN1 | O75460 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.39 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3924361 | 0.87 | ESR1 (1.00) | ESR1ESR2 | |
| SCHEMBL5981008 | 0.87 | ESR1 (0.72) | ESR1ESR2ERN1MGLLPDGFRB | |
| SCHEMBL5980256 | 0.78 | ESR1 (0.71) | ESR1ESR2ERN1MGLLPDGFRB | |
| SCHEMBL5980965 | 0.78 | ESR1 (0.71) | ESR1ESR2XDHERN1 | |
| SCHEMBL3926540 | 0.78 | ESR1 (1.00) | ESR1ESR2 | |
| SCHEMBL27647571 | 0.76 | ESR1 (0.52) | ESR1ESR2ERN1MGLLPDGFRB | |
| SCHEMBL3958458 | 0.74 | ESR1 (0.52) | ESR1ESR2XDHPDGFRBPDGFRA | |
| SCHEMBL27627364 | 0.73 | ESR1 (0.48) | ESR1ESR2XDHERN1PDGFRB | |
| SCHEMBL5981271 | 0.73 | ESR2 (0.72) | ESR1ESR2 | |
| SCHEMBL19270951 | 0.72 | MGLL (0.52) | ESR1ESR2ERN1MGLLPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7067524-B2 | Substituted phenyl naphthalenes as estrogenic agents | WYETH (US) | 2006-06-27 | — | — | US | disclosed |
| US-6914074-B2 | Substituted phenyl naphthalenes as estrogenic agents | WYETH (US) | 2005-07-05 | — | — | US | disclosed |
| US-20040225123-A1 | Substituted phenyl naphthalenes as estrogenic agents | MEWSHAW RICHARD E (US) | 2004-11-11 | — | — | US | disclosed |
| EP-1453782-A2 | SUBSTITUTED PHENYL NAPHTHALENES AS ESTROGENIC AGENTS | Wyeth (US) | 2004-09-08 | — | — | EP | disclosed |
| US-20030181519-A1 | Substituted phenyl naphthalenes as estrogenic agents | WYETH | 2003-09-25 | — | — | US | disclosed |
| WO-2003051805-A2 | SUBSTITUTED PHENYL NAPHTHALENES AS ESTROGENIC AGENTS | WYETH (US) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181519-A1 | Substituted phenyl naphthalenes as estrogenic agents | ESR2, ESR1, ESRRA | ESR1 2/4885ESR2 1/4885XDH 3948/4885 |
| US-20040225123-A1 | Substituted phenyl naphthalenes as estrogenic agents | ESR2, ESR1, ESRRA | ESR1 2/4885ESR2 1/4885XDH 3948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.